Royalty Pharma Plc Earnings

Royalty Pharma Plc’s revenue jumped 0.05% since last year same period to $568.25Mn in the Q1 2025. On a quarterly growth basis, Royalty Pharma Plc has generated -4.34% fall in its revenue since last 3-months.

Royalty Pharma Plc’s net profit jumped 4888.47% since last year same period to $238.35Mn in the Q1 2025. On a quarterly growth basis, Royalty Pharma Plc has generated 14.59% jump in its net profits since last 3-months.

Royalty Pharma Plc’s net profit margin jumped 4886.11% since last year same period to 41.94% in the Q1 2025. On a quarterly growth basis, Royalty Pharma Plc has generated 19.78% jump in its net profit margins since last 3-months.

Royalty Pharma Plc’s price-to-earnings ratio after this Q1 2025 earnings stands at 14.23.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current quarter stand at 0.95 - a -9.46% fall from last quarter’s estimates.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current year stand at 0.95.

Royalty Pharma Plc’s earning per share (EPS) jumped 7.87% since last year same period to 1.06 in the Q1 2025. This indicates that the Royalty Pharma Plc has generated 7.87% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Royalty Pharma Plc’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Royalty Pharma Plc’s return on equity (ROE) stands at 0.18.

Royalty Pharma Plc declared 0.22 dividend per share during the earnings announcement for Q1 2025.